Literature DB >> 18951702

Causative factors affecting peripheral neuropathy in burn patients.

Michael Y Lee1, Gloria Liu, Vicki Kowlowitz, Jeong Hye Hwang, Jung Hwan Lee, Kyoung Hyo Choi, Eun Shin Lee.   

Abstract

Peripheral neuropathy in burn patients may be frequently missed in clinical settings. Although its incidence has been reported, little is known regarding the factors that cause burn-related peripheral neuropathy. A retrospective chart review of the demographic and clinical characteristics of patients admitted to a university hospital based burn center was conducted to explore the characteristics of burn-related neuropathy and factors affecting its types or extent. The variables collected were gender, age, length of hospital stay, site and surface area of burn, type of burn, and electrodiagnostic findings. We found that flame injuries, and third degree injuries were the most common in patients with peripheral neuropathy. Axonotmesis was more common than demyelinating injury and polyneuropathy was more common than mononeuropathy. Higher degree and larger area burns were more frequently associated with axonotmesis than with demyelination. Length of hospital stay was significantly longer in patients with axonotmesis. Overall, more severe burns showed a significant association with axonotmesis and a tendency to be related to polyneuropathy.

Entities:  

Mesh:

Year:  2008        PMID: 18951702     DOI: 10.1016/j.burns.2008.08.009

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  2 in total

Review 1.  Peripheral Neuropathy and Nerve Compression Syndromes in Burns.

Authors:  Amy L Strong; Shailesh Agarwal; Paul S Cederna; Benjamin Levi
Journal:  Clin Plast Surg       Date:  2017-07-21       Impact factor: 2.017

2.  Chronic pain following physical and emotional trauma: the station nightclub fire.

Authors:  Rachel Egyhazi; Felipe Fregni; Gabriela L Bravo; Nhi-Ha T Trinh; Colleen M Ryan; Jeffrey C Schneider
Journal:  Front Neurol       Date:  2014-06-02       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.